Citius Oncology, Inc. (CTOR) vs Gain Therapeutics, Inc. (GANX)

A side-by-side comparison of Citius Oncology, Inc. and Gain Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

CTOR

Citius Oncology, Inc.

$83M

$0.89HealthcareDelayed quote: Oct 6, 2026, 10:10 AM EDT

GANX

Gain Therapeutics, Inc.

$73M

$1.71HealthcareDelayed quote: Oct 6, 2026, 10:15 AM EDT

Total return — CTOR vs GANX

growth of $100 · dividends reinvested · last 2y

CTOR -92.4% (-72.4%/yr)GANX +45.7% (+20.7%/yr)GANX compounded faster over this window

Log scale — wide-divergence pair

CTOR GANX

CTOR vs GANX: by the numbers

•CTOR is the larger company ($83M vs $73M market cap).
•Both run net losses; GANX's is the smaller (0.00% vs -648.32% net margin).

Metrics side by side

Valuation

Metric	CTOR	GANX
Forward P/E	8.90	N/A
P/S ratio	11.65	N/A
P/B ratio	2.05	6.46

Profitability

Metric	CTOR	GANX
Gross margin	0.00%	0.00%
Operating margin	0.00%	0.00%
Net margin	-648.32%	0.00%
ROE	-114.06%	-178.06%
ROIC	-88.72%	-159.24%

Growth (annualized)

Metric	CTOR	GANX
Total return CAGR (5Y)	N/A	-25.06%

Go deeper

Full CTOR analysis Full GANX analysis Interactive comparison tool

Dig into the metrics

Citius Oncology ROE Gain Therapeutics ROE Citius Oncology operating margin Gain Therapeutics operating margin Citius Oncology revenue growth Gain Therapeutics revenue growth Citius Oncology free cash flow Gain Therapeutics free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.